What Is Alpha-MSH? Benefits, Research & Safety

The melanocyte-stimulating hormones were first characterised in the 1950s when Aaron Lerner and colleagues isolated substances from pituitary extracts that darkened frog skin. α-MSH was identified as a key active component. The relationship between α-MSH and ACTH was established when researchers discovered that both derived from the same precursor, proopiomelanocortin (POMC). This explained their overlapping biological activities and established the melanocortin peptide family. Research in the 1980s and 1990s revealed α-MSH's potent anti-inflammatory effects, extending interest beyond pigmentation. Studies showed it could inhibit fever, reduce inflammatory cytokines, and protect tissues from inflammatory damage. The cloning of melanocortin receptors in the 1990s enabled understanding of how α-MSH achieves its diverse effects. This led to structure-activity studies and development of synthetic analogues with specific receptor preferences. Afamelanotide (Melanotan I) was developed as a stable α-MSH analogue and eventually approved (as Scenesse) for erythropoietic protoporphyria, a rare disease causing severe photosensitivity. This represented the first approved therapeutic use of an α-MSH analogue. Research continues into α-MSH-based therapies for inflammatory conditions, though short half-life and broad receptor activity present development challenges.